Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: economics

References

• COAG. Council of Australian Governments meeting report. Canberra: COAG, 2006. [Accessed 10 Aug 2007.] Available from URL:, , http://www.coag.gov.au/meetings/140706/docs/nap_mental_health.pdf.
   Google Scholar
• Andrews G. It would be cost-effective to treat more people with mental disorders. Aust N Z J Psychiatry 2006; 40: 613–615
   PubMed Web of Science ®Google Scholar
• Knapp M. Costs of schizophrenia. Br J Psychiatry 1997; 171: 509–518
   PubMed Web of Science ®Google Scholar
• Knapp M. Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand Suppl 2000; 102: 15–18
   Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004; 30: 279–293
   PubMed Web of Science ®Google Scholar
• Berk ML, Monheit AC. The concentration of health care expenditures, revisited. Health Aff (Millwood) 2001; 20: 9–18
   PubMed Web of Science ®Google Scholar
• Jablensky, AV, McGrath, J, Herrman, H., et al. People living with psychotic illness: an Australian study 1997–98. Canberra: Commonwealth of Australia, 1999.
   Google Scholar
• Murray CL, Lopez AD. The global burden of disease. Harvard University Press, Cambridge, MA 1996
   Google Scholar
• Mathers, C, Vos, T, Stevenson, C. The burden of disease and injury in Australia. AIHW cat. No. PHE 17. Canberra: Australian Institute of Health and Welfare, 1999.
   Google Scholar
• Begg S, Vos T, Barker B, Stevenson C, Stanley L, Lopez A. The burden of disease and injury in Australia. AIHW, Canberra 2003; 2007
   Google Scholar
• Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry 2004; 184: 526–533
   PubMed Web of Science ®Google Scholar
• Hall W, Goldstein G, Andrews G, Lapsley H, Bartels R, Silove D. Estimating the economic costs of schizophrenia. Schizophr Bull 1985; 11: 598–610
   PubMed Web of Science ®Google Scholar
• Andrews G. The cost of schizophrenia revisited. Schizophr Bull 1991; 17: 389–394
   PubMed Web of Science ®Google Scholar
• Langley-Hawthorne, C. Modeling the lifetime costs of treating schizophrenia in Australia. Clin Ther 1997; 19:1470–1495; discussion 1424–1475.
   PubMed Web of Science ®Google Scholar
• Carr VJ, Neil AL, Halpin SA, Holmes S, Lewin TJ. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 2003; 37: 31–40
   PubMed Web of Science ®Google Scholar
• Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. Med J Aust 2000; 172: 592–596
   PubMed Web of Science ®Google Scholar
• Mathers CD, Vos ET, Stevenson CE, Begg SJ. The burden of disease and injury in Australia. Bull World Health Organ 2001; 79: 1076–1084
   PubMed Web of Science ®Google Scholar
• Vos T, Mathers C, Herrman H, et al. The burden of mental disorders in Victoria, 1996. Soc Psychiatry Psychiatr Epidemiol 2001; 36: 53–62
   PubMed Web of Science ®Google Scholar
• Dewa CS, Remington G, Herrmann N, Fearnley J, Goering P. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther 2002; 24: 1466–1476
   PubMed Web of Science ®Google Scholar
• Crown WH, Neslusan C, Russo PA, Holzer S, Ozminkowski R, Croghan T. Hospitalization and total medical costs for privately insured persons with schizophrenia. Adm Policy Ment Health 2001; 28: 335–351
   PubMed Web of Science ®Google Scholar
• Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001; 52: 805–811
   PubMed Web of Science ®Google Scholar
• Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. J Clin Psychiatry 2001; 62: 749–756
   PubMed Web of Science ®Google Scholar
• Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003; 107: 222–232
   PubMed Web of Science ®Google Scholar
• Thornicroft G, Leese M, Tansella M, et al. Gender differences in living with schizophrenia. A cross-sectional European multi-site study. Schizophr Res 2002; 57: 191–200
   PubMed Web of Science ®Google Scholar
• Sytema S, Burgess P. Continuity of care and readmission in two service systems: a comparative Victorian and Groningen case-register study. Acta Psychiatr Scand 1999; 100: 212–219
   PubMed Web of Science ®Google Scholar
• Harvey CA, Fielding JM. The configuration of mental health services to facilitate care for people with schizophrenia. Med J Aust 2003; 178 (Suppl): S49–52
   Google Scholar
• Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003; 37: 55–61
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries D, Zhu B, Ernst F, Swartz M, Swanson J. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006; 67: 453–460
   PubMed Web of Science ®Google Scholar
• Burns T, Christova L, Cooper S, et al. Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study. Acta Psychiatr Scand 2006; 113: 126–134
   PubMed Web of Science ®Google Scholar
• Kulkarni, J, De Castella, AR, Filia, KM, et al. The Australian SCAP study: real-world schizophrenia: outcomes. Aust N Z J Psychiatry 2006; (in press).
   PubMed Web of Science ®Google Scholar
• Australian Government Department of Health and Ageing. Canberra: Australian Government Department of Health and Ageing. [Accessed 10 March 2003.] Available from URL:, , http://www.health.gov.au/casemix/costing/fc_r4.htm.
   Google Scholar
• Carr V, Neil A, Halpin S, Holmes S. Costs of psychosis in urban Australia. Australian Government Department of Health and Ageing, Canberra 2002
   Google Scholar
• Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13: 1–7
   PubMed Web of Science ®Google Scholar
• Lehman AF, Fischer EP, Postrado L, et al. The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophr Bull 2003; 29: 247–256
   PubMed Web of Science ®Google Scholar
• Carr VJ, Lewin TJ, Neil AL, Halpin SA, Holmes S. Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. Br J Psychiatry 2004; 184: 517–525
   PubMed Web of Science ®Google Scholar
• Michie PT, Budd TW, Todd J, et al. Duration and frequency mismatch negativity in schizophrenia. Clin Neurophysiol 2000; 111: 1054–1065
   PubMed Web of Science ®Google Scholar
• Access Economics. Schizophrenia: costs. An analysis of the burden of schizophrenia and related suicide in Australia. SANE Australia, 2002.
   Google Scholar
• Steinwachs DM, Kasper JD, Skinner EA. Patterns of use and costs among severely mentally ill people. Health Aff (Millwood) 1992; 11: 178–185
   PubMed Web of Science ®Google Scholar